BrainStorm Cell Therapeutics Inc.
Tel Aviv
424 articles about BrainStorm Cell Therapeutics Inc.
-
BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at NYSCF 2021 VIRTUAL Meeting
10/18/2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Therapeutic Benefits of MSC-NTF (NurOwn®) Exosomes in Acute Lung Injury Models" at the NYSCF 2021 VIRTUAL Meeting, being held on October 19-20, 2021.
-
Clinical Catch-Up: October 11-15
10/18/2021
It was yet another busy week for clinical trial announcements. Take a look. -
Phase 2 Clinical Trial Data of NurOwn® in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
10/14/2021
BrainStorm Cell Therapeutics Inc. will present findings from a multicenter, open label clinical trial of NurOwn® in progressive multiple sclerosis.
-
BrainStorm announced positive data from a Phase II safety and efficacy study of NurOwn in progressive MS on Thursday morning.
-
BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting October 6th, 2021
10/6/2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "CSF biomarker correlations with primary outcome in NurOwn Phase 3 clinical trial" will be presented as a scientific poster at the fully digital 2021 Northeast Amyotrophic Lateral Sclerosis Consortium® (NEALS) conference.
-
BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa
10/4/2021
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced that Stacy Lindborg, Ph.D., Executive Vice President and Head of Global Clinical Research, will deliver a presentation at the 2021 Cell & Gene Meeting on the Mesa, being held as a hybrid conference October 12-14, and October 19-20, 2021.
-
BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS
10/1/2021
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced that a scientific abstract titled "Phase 2 Safety and Efficacy Study of Intrathecal MSC-NTF cells in Progressive Multiple Sclerosis" will be presented in an oral presentation at the fully digital 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
-
Amylyx’s decision to submit the NDA, announced Wednesday morning, came on the heels of recent discussions with the FDA, including a pre-NDA meeting held on July 15.
-
BrainStorm Announces Second Quarter 2021 Financial Results and Provides a Corporate Update
8/5/2021
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced financial results for the first quarter ended June 30, 2021 and provided a corporate update.
-
The panels discussed key issues such as expanded access programs (EAPs), clinical trial diversity, conditional approval pathways, and patient experience data.
-
BrainStorm Increases Commercial Manufacturing Capacity; Granted GMP Certification for a Second Production Site in Israel
7/27/2021
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced that is has received Good Manufacturing Practice approval from the Israel Ministry of Health for three state-of-the-art cleanrooms leased by the Company at the Tel Aviv Sourasky Medical Center in Tel Aviv, Israel.
-
BrainStorm to Announce Second Quarter Financial Results and Provide a Corporate Update
7/26/2021
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced that the Company will hold a conference call to update shareholders on financial results for the second quarter ended June 30, 2021, and provide a corporate update, at 8:00 a.m. Eastern Time on August 05, 2021.
-
Brainstorm Announces Expansion of NurOwn® IP Portfolio with Grant and Allowance of Multiple Patents and Applications in Major Markets
6/15/2021
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the grant and/or allowance of a series of patents and patent applications
-
Not everyone is so confident that Aduhelm will transform the Alzheimer’s drug development landscape.
-
BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at ISCT 2021 New Orleans VIRTUAL Meeting
5/25/2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Molecular Mechanisms Underlying MSC-NTF (NurOwn®) Exosome Benefits in a Mouse LPS-induced ARDS Model" at the ISCT 2021 New Orleans VIRTUAL Meeting, being held from May 25-28, 2021.
-
There is also a tacit acknowledgment in the industry that the ALSFRS-R (revised) scale needs to evolve.
-
BrainStorm to Announce First Quarter Financial Results and Provide a Corporate Update
4/19/2021
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced that the Company will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2021, and provide a corporate update, at 8:00 a.m. Eastern Time on April 26, 2021.
-
BrainStorm Announces Positive Topline Data in Phase 2 Study Evaluating NurOwn® as a Treatment for Progressive MS
3/24/2021
BrainStorm Cell Therapeutics Inc . (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today topline data from the Company's Phase 2 trial evaluating three repeated administrations of NurOwn® (MSC-NTF cells), each given 2 months apart, as a treatment for progressive multiple sclerosis (MS).
-
BrainStorm's Nurown Trial Shows Promising Top-Line Results for Progressive Multiple Sclerosis
3/24/2021
The study involved observations in neurologic function, cognition and biomarkers in three repeated administrations of Nurown®, which were given two months apart. -
BrainStorm to Present at SVB Leerink 10th Global Healthcare Conference
2/23/2021
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that members of the management team will participate in the 10th Annual SVB Leerink Global Healthcare Conference.